Persistent plasma and RBC fatty acid abnormalities in children and adolescents with cystic fibrosis on highly effective CFTR modulators

Despite therapeutic and nutritional advances in CF treatment, EFAD remains prevalent and underrecognized in the CF population. The high risk of developing EFAD in pwCF with severe CFTR genotypes warrants the inclusion of the FA testing as a standard of care of these individuals.